News & Updates

Watch-and-wait approach feasible for therapy-responsive rectal cancer

Survival outcomes do not differ between patients with locally advanced rectal cancer treated with mandatory total mesorectal excision (TME) and those on selective watch-and-wait (WW) strategies following total neoadjuvant therapy (TNT), reports a study.

Watch-and-wait approach feasible for therapy-responsive rectal cancer

a day ago

VIDEO: Apalutamide’s tolerability in prostate cancer patients

a day ago by

Dr Darren Poon, Specialist in Clinical Oncology at Hong Kong Sanatorium & Hospital and Honorary Clinical Associate Professor at the Chinese University of Hong Kong, discusses apalutamide’s tolerability in prostate cancer patients.

VIDEO: Apalutamide’s tolerability in prostate cancer patients

a day ago

Neoadjuvant therapy extends survival in left-sided resectable pancreatic cancer

17 May 2025

Patients with left-sided resectable pancreatic cancer (RPC) enjoy improved overall survival (OS) with neoadjuvant therapy compared with upfront surgery, a recent study has shown.

Neoadjuvant therapy extends survival in left-sided resectable pancreatic cancer

17 May 2025

Management of NSCLC harbouring EGFR exon 20 insertion mutations

16 May 2025 by

Non-small-cell lung cancer (NSCLC) with EGFR exon 20 insertion (exon20ins) mutations is often resistant to approved EGFR tyrosine kinase inhibitors (TKIs). At an industry-sponsored symposium held during the 28^th Congress of the Asian Pacific Society of Respirology, Dr James Ho, Specialist in Respiratory Medicine in Hong Kong, reviewed the biological properties of these mutations and the role of amivantamab, the first EGFR-MET bispecific antibody with proven efficacy in patients with metastatic NSCLC harbouring EGFR exon20ins mutations.

Management of NSCLC harbouring EGFR exon 20 insertion mutations

16 May 2025

CAR T-cell therapy improves survival in non-Hodgkin lymphoma

15 May 2025

Treatment with chimeric antigen receptor T-cell therapies (CAR-TCT) results in significant improvements in overall (OS) and progression-free survival (PFS) among patients with refractory non-Hodgkin lymphoma (NHL) but shows no substantial effect on event-free survival (EFS), reports a study.

CAR T-cell therapy improves survival in non-Hodgkin lymphoma

15 May 2025

First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression

15 May 2025 by

First-line treatment with tislelizumab plus chemotherapy showed better survival outcomes and response among patients with locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC), particularly those with high PD-L1 expression, compared with chemotherapy alone, according to a subgroup analysis of the phase III RATIONALE-304 trial presented at ELCC 2025.

First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression

15 May 2025

World’s first AI model for thyroid cancer diagnosis achieves high accuracy

15 May 2025 by

The world’s first artificial intelligence (AI) model for diagnosis of well-differentiated thyroid cancer, developed by researchers from the University of Hong Kong (HKU), has demonstrated high accuracy in staging and risk classification based on analysis of semi-structured free-text clinical notes.

World’s first AI model for thyroid cancer diagnosis achieves high accuracy

15 May 2025

AML treatment efficacy varies by status, age, cytogenetic risk

14 May 2025

Some of the important treatment options for patients with acute myeloid leukaemia (AML) include chemotherapy, targeted therapy, and immunotherapy, but the efficacy of these treatments may vary depending on AML status, age, and cytogenetic risk, according to a study.

AML treatment efficacy varies by status, age, cytogenetic risk

14 May 2025

Cardio-onco collab may enhance safety of nivolumab anticancer therapy

14 May 2025

The safety of nivolumab anticancer therapy may be improved through close collaboration between cardiology and oncology specialists, which can help detect cardiac complications early and manage these conditions effectively, suggests a study.

Cardio-onco collab may enhance safety of nivolumab anticancer therapy

14 May 2025

MIRASOL final analysis: MIRV remains superior to chemo for ovarian cancer

13 May 2025 by

In the final overall survival (OS) analysis of the phase III MIRASOL trial, the survival benefit previously reported with the antibody drug conjugate mirvetuximab soravtansine (MIRV) remains superior to investigator’s choice chemotherapy (ICC) for the treatment of folate receptor alpha-positive, platinum-resistant ovarian cancer (FRα+ PROC).

MIRASOL final analysis: MIRV remains superior to chemo for ovarian cancer

13 May 2025

News & Updates

Filter by Specialty:

Specialty:

Watch-and-wait approach feasible for therapy-responsive rectal cancer

Watch-and-wait approach feasible for therapy-responsive rectal cancer

VIDEO: Apalutamide’s tolerability in prostate cancer patients

VIDEO: Apalutamide’s tolerability in prostate cancer patients

Neoadjuvant therapy extends survival in left-sided resectable pancreatic cancer

Neoadjuvant therapy extends survival in left-sided resectable pancreatic cancer

Management of NSCLC harbouring EGFR exon 20 insertion mutations

Management of NSCLC harbouring EGFR exon 20 insertion mutations

CAR T-cell therapy improves survival in non-Hodgkin lymphoma

CAR T-cell therapy improves survival in non-Hodgkin lymphoma

First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression

First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression

World’s first AI model for thyroid cancer diagnosis achieves high accuracy

World’s first AI model for thyroid cancer diagnosis achieves high accuracy

AML treatment efficacy varies by status, age, cytogenetic risk

AML treatment efficacy varies by status, age, cytogenetic risk

Cardio-onco collab may enhance safety of nivolumab anticancer therapy

Cardio-onco collab may enhance safety of nivolumab anticancer therapy

MIRASOL final analysis: MIRV remains superior to chemo for ovarian cancer

MIRASOL final analysis: MIRV remains superior to chemo for ovarian cancer